Please upgrade your browser.
According to a study, patients with intermediate- or poor-risk disease, median overall survival was not estimable in the nivolumab/ipilimumab group vs 25.9 months in the sunitinib arm (hazard ratio [HR] = 0.63, P < .0001). Median progression-free survival was 11.6 vs 8.4 months (HR = 0.82, P = not significant). The objective response rate was 41.6% vs 26.5% (P < .0001). The efficacy of the combination was not established in patients with favorable-risk disease.
Combination immunotherapy with IL-2 surface-modified tumor cell vaccine and PD-1 blockade against renal cell carcinoma
Studies show that immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma.
A new study published in JAMA Internal Medicine suggests those who frequently eat organic foods may have a lower risk of developing cancer.
Colon and kidney cancer and lymphoma were among the types of cancer for which the correlation was strongest.
Wakame seaweed may have cancer-fighting properties. A study found that specific compounds extracted from the seaweed were effective at inhibiting the growth of colon and kidney cancer cells.
ESMO is only 7 days away. Here is an inside look at some of the trials that will be discussed.
Cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich, Germany.
Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC): A Contemporary Review and Practical Discussion of the Differential Diagnosis for HLRCC-Associated Renal Cell Carcinoma
Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is an uncommon disorder with germline-inactivating mutations in the fumarate hydratase ( FH) gene. The kidney cancers that develop in patients with HLRCC are often unilateral and solitary, with a potentially aggressive clinical course; morphologic identification of suspicious cases is of the utmost importance.
In clinical trials evaluating cancer interventions, there was no significant association between progression-free survival and health-related quality of life, according to research published in JAMA Internal Medicine.
What Makes the Nobel-Winning Breakthroughs in Immunotherapy So Revolutionary Read more: https://www.smithsonianmag.com/science-nature/nobel-winning-breakthroughs-in-immunotherapy-revolutionary-1809704
This week, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their breakthrough discoveries in immunotherapy. This article by Smithsonian Magazine explains the importance of this approach in treating cancer.
|Powered by NeonCRM|